Lipocine (NASDAQ:LPCN) has been given a $3.00 target price by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 60.43% from the stock’s previous close.
LPCN has been the topic of a number of other research reports. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $11.00 price objective on shares of Lipocine in a research note on Thursday. Canaccord Genuity downgraded Lipocine from a “buy” rating to a “hold” rating in a report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $13.50.
Lipocine (LPCN) opened at $1.87 on Friday. The firm has a market capitalization of $39.64, a P/E ratio of -1.95 and a beta of 0.11. Lipocine has a 12-month low of $1.67 and a 12-month high of $5.33.
WARNING: This article was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/01/12/lipocine-lpcn-pt-lowered-to-3-00-at-hc-wainwright.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.